Antibody–drug conjugates in triple negative breast cancer
| Autor: | Nancy Tray, Francisco J. Esteva, Sylvia Adams |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Drug Oncology Cancer Research medicine.medical_specialty Immunoconjugates Breakthrough therapy medicine.drug_class media_common.quotation_subject Triple Negative Breast Neoplasms Disease Poly(ADP-ribose) Polymerase Inhibitors Antibodies Monoclonal Humanized Monoclonal antibody 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Cytotoxic T cell Triple-negative breast cancer media_common Clinical Trials as Topic Membrane Glycoproteins biology business.industry Antibodies Monoclonal General Medicine 030104 developmental biology 030220 oncology & carcinogenesis Drug delivery biology.protein Camptothecin Female Antibody business |
| Zdroj: | Future Oncology. 14:2651-2661 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2018-0131 |
| Popis: | Triple negative breast cancer (TNBC) is a heterogeneous disease that comprises 15–20% of all breast cancers and is more frequently seen in younger women, African–Americans, and BRCA1 expression. Advanced TNBC carries aggressive features and is associated with overall poor outcomes. Unfortunately, there are no targeted therapies available for non-BRCA associated TNBC, which remains a high unmet therapeutic need. One emerging treatment modality includes antibody–drug conjugates which are highly selective monoclonal antibodies conjugated to cytotoxic agents, designed to deliver cytotoxic drugs to antigen-expressing tumor cells. This review will highlight three antibody–drug conjugates currently being evaluated in TNBC (CDX-011, SGN-LIV1a, IMMU-132), including one that has been given Breakthrough Therapy designation from the US FDA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|